Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
公司代碼XCUR
公司名稱Exicure Inc
上市日期May 09, 2018
CEOYoo (Andy)
員工數量7
證券類型Ordinary Share
年結日May 09
公司地址2430 N. Halsted St.
城市CHICAGO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編60614
電話18476731707
網址https://www.exicuretx.com/
公司代碼XCUR
上市日期May 09, 2018
CEOYoo (Andy)